Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels.

ABSTRACT:

Background

Wilms tumor 1 (WT1) is over-expressed in numerous cancers with respect to normal cells, and has either a tumor suppressor or oncogenic role depending on cellular context. This gene is associated with numerous alternatively spliced transcripts, which initiate from two different unique first exons within the WT1 and the alternative (A)WT1 promoter intervals. Within the hematological system, WT1 expression is restricted to CD34+/CD38- cells and is undetectable after differentiation. Detectable expression of this gene is an excellent marker for minimal residual disease in acute myeloid leukemia (AML), but the underlying epigenetic alterations are unknown.

Methods

To determine the changes in the underlying epigenetic landscape responsible for this expression, we charac

SUBMITTER: Guillaumet-Adkins A 

PROVIDER: S-EPMC3900738 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature